大麻二酚将NF-κB转化为胶质母细胞瘤抑癌因子并具明确抗氧化特性
该研究在大鼠胶质瘤细胞药物基因组学筛选中发现,非精神活性大麻素大麻二酚(CBD)可将NF-κB转为抑癌因子;在人原代胶质母细胞瘤干细胞样细胞(hGSC)中,CBD促进RELA的DNA结合并阻止其丝氨酸311磷酸化,从而介导细胞毒性;低活性氧(ROS)的hGSC对CBD敏感,高ROS则阻断CBD诱导的细胞死亡,提示ROS水平可作为CBD敏感性的预测生物标志物。
要点
- CBD通过促进RELA的DNA结合并抑制其Ser311磷酸化,将NF-κB转化为抑癌因子。
- 低ROS水平的hGSC对CBD敏感,高ROS阻断CBD诱导的细胞死亡。
- ROS水平可作为预测GBM对CBD敏感性的生物标志物。
核心结论
- 临床已批准药物CBD可将NF-κB转化为抑癌因子,为GBM治疗提供有前景的药物重定位选项。
研究设计与样本
- 药物基因组学研究使用一组转基因胶质瘤细胞,并在更大规模的人原代胶质母细胞瘤干细胞样细胞(hGSC)中验证。
- 采用药理学实验、基因表达谱分析、生化与细胞生物学实验,并用原位体内模型及人GBM数据集生物信息学分析验证。
主要发现
- CBD促进NF-κB亚基RELA的DNA结合,同时阻止RELA在丝氨酸311位点的磷酸化。
- 持续DNA结合但缺乏磷酸化丝氨酸311的RELA介导hGSC细胞毒性。
- 在一组hGSC中观察到广泛的CBD敏感性,该组以低活性氧(ROS)水平为特征。
- 其他肿瘤中高ROS含量阻断CBD诱导的hGSC死亡。
- ROS水平可作为CBD敏感肿瘤的预测生物标志物。
临床怎么用
- CBD(Epidiolex,用于小儿神经科的抗惊厥药)可能重定位用于GBM治疗。
- 临床可检测肿瘤ROS水平以筛选可能对CBD敏感的GBM患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The transcription factor NF-κB drives neoplastic progression of many cancers including primary brain tumors (glioblastoma [GBM]). Precise therapeutic modulation of NF-κB activity can suppress central oncogenic signaling pathways in GBM, but clinically applicable compounds to achieve this goal have remained elusive. METHODS: In a pharmacogenomics study with a panel of transgenic glioma cells, we observed that NF-κB can be converted into a tumor suppressor by the non-psychotropic cannabinoid cannabidiol (CBD). Subsequently, we investigated the anti-tumor effects of CBD, which is used as an anticonvulsive drug (Epidiolex) in pediatric neurology, in a larger set of human primary GBM stem-like cells (hGSC). For this study, we performed pharmacological assays, gene expression profiling, biochemical, and cell-biological experiments. We validated our findings using orthotopic in vivo models and bioinformatics analysis of human GBM datasets. RESULTS: We found that CBD promotes DNA binding of the NF-κB subunit RELA and simultaneously prevents RELA phosphorylation on serine-311, a key residue that permits genetic transactivation. Strikingly, sustained DNA binding by RELA-lacking phospho-serine 311 was found to mediate hGSC cytotoxicity. Widespread sensitivity to CBD was observed in a cohort of hGSC defined by low levels of reactive oxygen species (ROS), while high ROS content in other tumors blocked CBD-induced hGSC death. Consequently, ROS levels served as a predictive biomarker for CBD-sensitive tumors. CONCLUSIONS: This evidence demonstrates how a clinically approved drug can convert NF-κB into a tumor suppressor and suggests a promising repurposing option for GBM therapy.
引用
- Volmar MNM, Cheng J, Alenezi H, et al. Cannabidiol converts NF-κB into a tumor suppressor in glioblastoma with defined antioxidative properties. Neuro Oncol. 2021. PMID: 33864076. doi:10.1093/neuonc/noab095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。